Affimed Current Ratio 2014-2024 | AFMDQ
Affimed current ratio from 2014 to 2024. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Affimed Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2024-09-30 |
$0.04B |
$0.02B |
1.93 |
| 2024-06-30 |
$0.05B |
$0.02B |
2.71 |
| 2024-03-31 |
$0.07B |
$0.02B |
3.06 |
| 2023-12-31 |
$0.09B |
$0.03B |
3.25 |
| 2023-09-30 |
$0.12B |
$0.03B |
3.70 |
| 2023-06-30 |
$0.14B |
$0.03B |
5.05 |
| 2023-03-31 |
$0.18B |
$0.03B |
5.21 |
| 2022-12-31 |
$0.21B |
$0.04B |
5.66 |
| 2022-09-30 |
$0.23B |
$0.04B |
5.65 |
| 2022-06-30 |
$0.27B |
$0.06B |
4.90 |
| 2022-03-31 |
$0.20B |
$0.07B |
3.13 |
| 2021-12-31 |
$0.24B |
$0.08B |
3.20 |
| 2021-09-30 |
$0.24B |
$0.08B |
3.07 |
| 2021-06-30 |
$0.27B |
$0.08B |
3.38 |
| 2021-03-31 |
$0.30B |
$0.08B |
3.93 |
| 2020-12-31 |
$0.17B |
$0.08B |
2.25 |
| 2020-09-30 |
$0.12B |
$0.05B |
2.24 |
| 2020-06-30 |
$0.11B |
$0.04B |
2.93 |
| 2020-03-31 |
$0.10B |
$0.04B |
2.59 |
| 2019-12-31 |
$0.12B |
$0.04B |
3.01 |
| 2019-09-30 |
$0.09B |
$0.03B |
2.73 |
| 2019-06-30 |
$0.10B |
$0.03B |
3.48 |
| 2019-03-31 |
$0.12B |
$0.04B |
3.17 |
| 2018-12-31 |
$0.13B |
$0.04B |
3.01 |
| 2018-09-30 |
$0.05B |
$0.01B |
3.66 |
| 2018-06-30 |
$0.06B |
$0.01B |
5.35 |
| 2018-03-31 |
$0.07B |
$0.01B |
6.58 |
| 2017-12-31 |
$0.05B |
$0.01B |
5.60 |
| 2017-09-30 |
$0.05B |
$0.01B |
6.43 |
| 2017-06-30 |
$0.06B |
$0.01B |
6.69 |
| 2017-03-31 |
$0.06B |
$0.01B |
9.13 |
| 2016-12-31 |
$0.05B |
$0.01B |
7.51 |
| 2016-09-30 |
$0.06B |
$0.01B |
6.27 |
| 2016-06-30 |
$0.07B |
$0.01B |
8.73 |
| 2016-03-31 |
$0.09B |
$0.01B |
8.76 |
| 2015-12-31 |
$0.09B |
$0.01B |
8.76 |
| 2015-09-30 |
$0.07B |
$0.01B |
10.42 |
| 2015-06-30 |
$0.08B |
$0.01B |
13.41 |
| 2015-03-31 |
$0.04B |
$0.01B |
9.27 |
| 2014-12-31 |
$0.05B |
$0.01B |
6.58 |
| 2014-09-30 |
$0.06B |
$0.01B |
7.29 |
| 2014-06-30 |
$0.00B |
|
0.00 |
| 2014-03-31 |
$0.00B |
|
0.00 |
| 2013-09-30 |
$0.00B |
|
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.009B |
|
Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V., is based in Heidelberg, Germany.
|
